Working… Menu

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01112345
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : July 16, 2014
Merck A.E., Greece
Information provided by (Responsible Party):
Merck KGaA, Darmstadt, Germany